

January 8, 2025

8:00

Baxter Shortage IV Solution Meeting

Does everyone feel comfortable – even with the large surge of people.

Agneda:

Check in with Hospitals:

Allina – ICS is demobilized, moving towards AAR/Hot wash. Removed Best Practice Alert from EPIC but still conserving and they are pleased that employees are supportive. LR bags remain limited along with the 3L – they continue to cancel procedures that use those but feel comfortable outside of those products.

HHS – Similar in that we stood down IC, but TEAMS channel is in operation for T & Th updates. Still conserving. Continue to message staff about the need to conserve. LR continue to monitor and not getting full allocation. High census.

YELLOW. Do not anticipate going to Red.

Fairview – Agree with others. In the last week or so they have experienced shortage with fluids with potassium additives and D10. **Are other sites having that experience?** HHS yes for D10, and Allina one week on hand, Fairview has not received these and will be compounding from D70 bags beginning soon.

CentraCare are working on demobilizing IC as well, while still conserving.

Northfield Higher census, no current demands that would move us to red. Continuing conservation methods

UPDATE

From [Baxter's website](#): December 19, 2024 (Last update in 2024 – no new update for 2025 as of 1/8/25)

- We are making continued strong progress at North Cove and have now restarted 8 of the 10 manufacturing lines at the site, which represent ~85% of the site's total pre-hurricane capacity.
- While the recently restarted lines will require time to ramp up, some of the earlier lines to restart are operating near pre-hurricane levels.
- We currently expect to be producing at pre-hurricane levels across the plant early in the first quarter of 2025.
- Note that it will take some time for product to flow through the distribution channels. To that end, we currently expect that North Cove's recovery to full production will translate to removal of allocations for the related product groups during the first quarter of 2025.

U.S. IV Solutions Allocations:

- Baxter communicated additional allocation increases for several IV product groups to U.S. customers and distributors, effective in phases beginning Dec. 16 and Dec. 30. Customers are advised that there is a typical 1 to 2-week lag time for product to flow through the full distribution network after allocation changes are implemented.
- Consistent with original year-end projections, Baxter has communicated its plans to reach 100% allocation for the majority of critical IV product groups by the end of 2024.
- Baxter's ability to adjust allocation levels is based on 1) the current and projected status of our North Cove remediation efforts, 2) our expectations regarding our ability to reallocate capacity from other Baxter facilities, and 3) temporary importation of certain products.
- To date, we have evaluated and approved hundreds of allocation exception requests to help support neonatal and pediatric patient needs.

Metro on call number: 612.873.9911 (24/7)

Next meeting: Feb 5 at 8:00